 |
|
|
| |
Ritonavir-boosted Danoprevir plus PegIFN Alfa-2a/Ribavirin (P/R) Demonstrates up to 100% SVR24 with 12 or 24 Weeks of Total Treatment in Treatment-Naive Patients with HCV Genotype 4 Infection in the DAUPHINE Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 Boston 2012
C. Hezode,1 M.L. Shiffman,2 C. Cooper,3 G.T. Everson,4 P. Marcellin,5 M. Rodriguez-Torres,6 M. Bourlière,7 S. Pol,8 D. Richardson,9 S. Le Pogam,10 I. Nájera,10 J. Zhou,11 M.T. Navarro,12 A. Voulgari,9 N.S. Shulman,12 E.S. Yetzer12
1University Paris XII, Hôpital Henri Mondor, Creteil, France; 2Liver Institute of Virginia, Richmond and Newport News, VA, USA; 3University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada; 4University of Colorado School of Medicine, Denver, CO, USA; 5Hôpital Beaujon, Clichy, France; 6Fundacion de Investigacion, San Juan, PR, USA; 7Hôpital Saint Joseph, Marseille, France; 8Hôpital Cochin, Universite Paris Descartes INSERM U1610, Paris, France; 9 Roche Products Ltd, Welwyn, United Kingdom; 10Hoffmann La Roche Inc, Nutley, NJ, USA; 11Roche Product Development - Asia Pacific, Shanghai, China; 12Genentech, South San Francisco, CA, USA
|
| |
|
|
|
|
|
